1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Ninlaro Looking Positive In MM Maintenance On Back Of TOURMALINE Data

 
• By Ian Haydock

Takeda's Ninlaro seems to have proved its mettle in the first major placebo-controlled trial assessing a proteasome inhibitor as a single-agent maintenance therapy in multiple myeloma.

Diagnosis of Multiple Myeloma. Test tubes or bottles for blood, stethoscope and laboratory hematology analysis surrounded by text title of diagnosis of Multiple Myeloma lie in the doctor workplace
Ixazomib Positive In Multiple Myeloma Maintenance • Source: Shutterstock

Single-agent Ninlaro (ixazomib) as maintenance therapy in multiple myeloma following autologous stem cell transplant (ASCT) reduced the risk of disease progression or death by around a third versus placebo, new data from a major study with the Takeda Pharmaceutical Co. Ltd. drug show.

Detailed data from the TOURMALINE-MM3 trial presented to the 60th American Society of Hematology (ASH) meeting in San Diego should help position the oral proteasome inhibitor as a new maintenance therapy option to extend the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.